Realizing our vision

Realizing our vision

Our team to deliver seRNAs
to patients

 

Our team to deliver seRNAs
to patients

 

Our Team to deliver seRNAs to patients

At STRD we have a team of biotech enthusiasts with experience and expertise from the pharmaceutical, R&D, clinical research, legal and financial fields. Together, we are committed to realize our vision for bringing seRNAs to patients to improve their lives.

Management

Dr. Bernd Hoffmann

CEO, CSO & Co-Founder

Dr. Georg Lautscham

Consultant, CCO, CBO

  • 20+ years experience in molecular biology and drug delivery
  • Entrepreneur and founder of numerous biotech companies
  • 20+ years biotech executive experience
  • Track record in strategic partnerships, licensing deals, financing rounds and M&As

It is not often in life that you get the opportunity to try something really important. The seRNA technology has the potential to develop new therapeutic approaches and thus to give patients hope and a better future. That is definitely big enough for me.

Dr. Bernd Hoffmann

mRNAs have had a massive impact on all our lives during the pandemic. Being part of a team that is aiming to develop this life saving technology further and applying it to some of the most devastating diseases is a privilege and an obligation that motivates us every day. Or as Albert Einstein put it: Once we accept our limits, we go beyond them.

Dr. Georg Lautscham

Dr. Bernd Hoffmann

CEO, CSO & Co-Founder

  • 20+ years experience in molecular biology and drug delivery
  • Entrepreneur and founder of numerous biotech companies

It is not often in life that you get the opportunity to try something really important. The seRNA technology has the potential to develop new therapeutic approaches and thus to give patients hope and a better future. That is definitely big enough for me.

Dr. Bernd Hoffmann

Dr. Georg Lautscham

Consultant, CCO, CBO

  • 20+ years biotech executive experience
  • Track record in strategic partnerships, licensing deals, financing rounds and M&As

mRNAs have had a massive impact on all our lives during the pandemic. Being part of a team that is aiming to develop this life saving technology further and applying it to some of the most devastating diseases is a privilege and an obligation that motivates us every day. Or as Albert Einstein put it: Once we accept our limits, we go beyond them.

Dr. Georg Lautscham

Advisory boards

Dr. Walter Wenninger

Supervisory board

  • Former Member Management Board Bayer AG, Healthcare.
  • Former Chairman Evotec AG.
  • Member Novo Holdings Advisory Board, DK.

In our industry it is not often that you see novel, disruptive technologies. mRNA clearly is such a case and has demonstrated its potential, in the prophylactic setting, already. To further improve and broaden this technology for better therapeutic interventions is the aim of the SRTD team and their seRNA approach. I see my role as a mentor and sounding board for the operational team, and I am excited to be part of the road ahead and the prospects seRNAs offer.

Dr. Walter Wenninger

Dr. Eckhard von Keutz

Consultant, Head Early Development

  • Former Senior Vice President and Head Translational Sciences at Bayer AG, Pharmaceuticals
  • 30+ years experience in Pharma R&D

I was attracted and thrilled by SRTD biotech‘s unique seRNAs platform which may offer hope for patients who are in urgent need for novel treatment modalities in indications of high medical need. It‘s great to work on a team of enthusiasts who are burning for science, who have the needs of patients in mind, and who are committed to making things happen. „The ones who are crazy enough to think they can change the world are the ones who do.“ (Steve Jobs).

Dr. Eckhard von Keutz